Oncotarget

Research Papers:

Thioredoxin reductase: A novel, independent prognostic marker in patients with hepatocellular carcinoma

Chunyan Li _, Yan Peng, Binglang Mao and Kun Qian

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:17792-17804. https://doi.org/10.18632/oncotarget.3785

Metrics: PDF 1829 views  |   HTML 1480 views  |   ?  


Abstract

Chunyan Li1,2, Yan Peng3, Binglang Mao4, Kun Qian5

1Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

2Biotherapy Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

3Department of Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

4The Medical Examination Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

5Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

Correspondence to:

Kun Qian, e-mail: hxjsqk023@126.com

Keywords: hepatocellular carcinoma, thioredoxin reductase, prognosis, recurrence, chinese

Received: March 12, 2015     Accepted: April 10, 2015     Published: April 23, 2015

ABSTRACT

Here we found that hepatocellular carcinoma (HCC) patients with recurrence outcome and nonsurvivors had significantly increased thioredoxin reductase (TrxR) serum levels on reoperation (P < 0.0001 and P < 0.0001). Multivariate regression analysis adjusted for common risk factors showed that TrxR was an independent predictor of recurrence (hazard ratios [HR] = 4.19; 95% confidence intervals [CI]: 3.21–7.08) and overall survival (HR = 5.56; 95% CI: 3.42–10.21). The area under the receiver operating characteristic curve of TrxR was 0.837 (95% CI, 0.794–0.881) for recurrence outcome and 0.901 (95% CI, 0.869–0.933) for mortality, which was superior to high-sensitivity-C-reactive protein and a-fetoprotein (P < 0.001). The preoperative serum TrxR level is an independent and significant indicator predictive of poor prognosis and early recurrence in patients with HCC, which offering reliable information for predicting survival.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3785